The Barbara Ann Karmanos Cancer Institute named Kathleen Fedoronko as the new chief nursing officer and vice president of Patient Care Services at Karmanos Cancer Hospital.
City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.
ConcertAI named Casey Graves general manager of Clinical Solutions. In this role, Graves will drive growth and innovation in real-world data and AI solutions for oncology research and clinical care, accelerating advances that improve outcomes for patients and healthcare providers.
Deirdre Saulet was named chief strategy officer at Jasper Health.
The Fund for Science and Technology announced an inaugural suite of grants and its plan to fund at least $500 million over the next four years to support transformational science and technology for people and the planet.
UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.
Allen Chao was named CEO of Zephyr AI, a company focused on utilizing artificial intelligence to accelerate drug development.
Qure.ai has appointed Javier J. Zulueta, previously professor of medicine at the Icahn School of Medicine at Mount Sinai in New York and pulmonary division chief at Mount Sinai Morningside Hospital, as chief medical officer for pulmonology.
Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.
Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.
